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ABSTRACT
◥
Antiretrovirals belonging to the human immunodeficiency virus
(HIV) protease inhibitor (HIV-PI) class exert inhibitory effects
across several cancer types by targeting tumor cells and its micro-
environment. Cervical carcinoma represents a leading cause of
morbidity and mortality, particularly in women doubly infected
with high-risk human papillomaviruses (HR-HPV) and HIV; of
note, combined antiretroviral therapy has reduced cervical car-
cinoma onset and progression in HIV-infected women. We
evaluated the effectiveness and mechanism(s) of action of
HIV-PI against cervical carcinoma using a transgenic model of
HR-HPV–induced estrogen-promoted cervical carcinoma
(HPV16/E2) and found that treatment of mice with ritonavir-
boosted HIV-PI, including indinavir, saquinavir, and lopinavir,
blocked the growth and promoted the regression of murine
cervical carcinoma. This was associated with inhibition of tumor
angiogenesis, coupled to downregulation of matrix metallopro-
teinase (MMP)-9, reduction of VEGF/VEGFR2 complex, and
concomitant upregulation of tissue inhibitor of metalloprotei-
nase-3 (TIMP-3). HIV-PI also promoted deposition of collagen
IV at the epithelial and vascular basement membrane and nor-
malization of both vessel architecture and functionality. In agree-
ment with this, HIV-PI reduced tumor hypoxia and enhanced the
delivery and antitumor activity of conventional chemotherapy.
Remarkably, TIMP-3 expression gradually decreased during pro-
gression of human dysplastic lesions into cervical carcinoma. This
study identified the MMP-9/VEGF proangiogenic axis and its
modulation by TIMP-3 as novel HIV-PI targets for the blockade
of cervical intraepithelial neoplasia/cervical carcinoma develop-
ment and invasiveness and the normalization of tumor vessel
functions. These findings may lead to new therapeutic indications
of HIV-PI to treat cervical carcinoma and other tumors in either
HIV-infected or uninfected patients.
Introduction
The DNA of high-risk human papillomaviruses (HR-HPV) is
detected in approximately 90% of uterine cervical carcinomas, with
HPV16 being the most prevalent HR-HPV type (1). Productive
infection of the uterine cervical epithelium is found in low-grade
cervical lesions, such as cervical intraepithelial neoplasia (CIN1/2), but
is largely decreased in advanced dysplasia (CIN3), owing to deregu-
lation of HPV gene expression associated with integration of the viral
genome in the host cell chromosomes (1). Although 70%–80% of
CIN1/2 regress spontaneously, a low fraction persists for long periods
of time, and it has become increasingly evident that persistency of
HR-HPV infection is the major risk factor for cervical carcinoma
development (1, 2). This most likely reflects the increased chance of
(stochastic) HPVDNA integration leading to upregulation of theHPV
E6 and E7 oncoproteins that, in turn, bind to the p53 and pRb tumor
suppressors promoting their degradation or inactivation, respective-
ly (1, 3). Accordingly, persistent HPV infection is also the main risk
factor for CIN/cervical carcinoma recurrence after excisional
treatment (4, 5).
The recent advent of effective preventative vaccines against
HR-HPV has raised hope for cervical carcinoma eradication. How-
ever, despite vaccination campaigns, HR-HPV infection is still the
most common sexually transmitted disease worldwide, with an
estimated global prevalence of 11.7% (6, 7). Preventative HPV
vaccines, in fact, are ineffective against already established infec-
tions. As a consequence, cervical carcinoma remains the fourth
most common cancer in women (the second in Africa), accounting
for a large part of morbidity and mortality worldwide (8), with 2%
projected increase in global burden by 2030 (6). These data point to
the need of developing new treatments to block cervical carcinoma
onset and progression.
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CIN incidence and aggressiveness are particularly dramatic in
human immunodeficiency virus (HIV)/HPV doubly infected wom-
en (9). In fact, HIV infection leads to increased prevalence, acquisition,
and persistence of HR-HPV infection (9). Furthermore, HR-HPV
infection can persist in both HIVþ and seronegative women even after
excision of low-grade CIN, leading to an overall 6% disease
recurrence (5).
In this context, recent epidemiologic studies showed that anti-
retroviral treatment in HIVþ women reduces the incidence and
progression of CIN and ultimately the incidence of invasive cervical
carcinoma (9, 10), although most of these studies did not discrim-
inated between HIV protease inhibitors’ (HIV-PI) and HIV reverse
transcriptase inhibitors’ antitumor effect. Of note, previous evi-
dence indicates that HIV-1 PIs, a class of antiretroviral drugs widely
used in HIVþ patients, exert direct antitumor effects, which are
independent of their antiviral activity. In particular, HIV-PIs can
impair endothelial and tumor cell capability of degrading the
extracellular matrix (ECM; refs. 11–18). As a consequence, HIV-
PIs block tumor invasion and angiogenesis, thus inhibiting the
growth of different tumor models including Kaposi sarcoma, the
most frequent tumor in HIV-infected individuals (11, 13–16, 19).
HIV-PIs block tumor and endothelial cell invasion via the func-
tional impairment of the matrix metalloproteinases (MMP), ECM-
degrading proteolytic enzymes, which play a central role in tumor
angiogenesis, invasion, and metastasis (11, 13–15, 17, 18, 20). Inter-
estingly, the HIV-PIs saquinavir (SQV), ritonavir (RTV) and, to a
lesser extent, indinavir (IDV), can inhibit the growth and invasion
of cultured CIN cells. This outcome is, in turn, due to inhibition of
both MMPs expression and activity through inactivation of the
Akt/Fra-1 signaling pathway, which is, instead, activated by the
HR-HPV oncoproteins E6/E7 (15, 19). These effects of HIV-PIs
occur at drug concentrations comparable with those present in
plasma of treated patients (12, 13, 17). Furthermore, at drug
concentrations above the therapeutic peak levels (50–100 mmol/L),
HIV-PI causes apoptosis in tumor cells of several tumor types,
including cervical carcinoma (13, 17, 21, 22). Finally, phase II clinical
trials have shown that use of HIV-PIs is safe and effective in classical
(non-HIV associated) Kaposi sarcoma occurring in elderly people (23)
and in CIN lesions developing in HIV-negative women (24).
On the basis of these findings, we have explored the effectiveness
and mechanism(s) of action of HIV-PIs against cervical carcinoma.
To this goal, we used a HPV16 E6/E7 transgenic mouse model of
HPV-induced estrogen-promoted cervical carcinoma, which well
recapitulates the natural stages of cervical carcinoma development
(HPV16/E2 mice) and is widely used for the evaluation of anti-
angiogenic and antitumor compounds (25). CIN progression in
both human cervical carcinoma and HPV16/E2 mice is promoted
by increasing the expression/activity of MMP-9 and VEGF both
beneath the stromal/epithelial junction and within the tumor mass,
which is directly correlated with tumor vessel density, as also
observed in human lesions (17, 20, 25, 26).
Here, we show that treatment of HPV16/E2 mice with either first-
(indinavir and saquinavir) or second-generation [lopinavir (LPV)]
HIV-PIs blocks the growth and promotes the regression of cervical
carcinoma. This effect was associated with inhibition of tumor angio-
genesis, MMP-9 activity, andVEGF binding toVEGFR2, coupled with
upregulation of tissue inhibitor of metalloproteinase-3 (TIMP-3).
Because of these actions, HIV-PIs induced tumor vessel normalization
and relieved tumor hypoxia in HPV16/E2 cervical carcinoma. These
findings shed light on the molecular mechanisms of HIV-PIs antitu-
mor effect and support the use of these drugs as new therapeutics




Generation of keratin 14 (K14)-HPV16 transgenic mice, main-
tained in the FVB/n background (Charles River Laboratories), and
17b-estradiol (E2) treatment for cervical carcinogenesis were reported
previously (25, 27). Briefly, at 1month of age, virgin, femaleHPV16/E2
mice, bred in the animal facility of Candiolo Cancer Institute
(Candiolo, Turin, Italy), were anesthetized through isoflurane anes-
thesia and slow-release pellets that deliver 17b-estradiol at doses of
0.05 mg over 60 days (Innovative Research of America Inc.) were
implanted below the dorsal back skin. Subsequent pellets were
implanted at 3 and 5months of age for a total of 6 months of hormone
treatment (25, 27). All animal procedures were approved by the Ethical
Committee of the University of Turin (Candiolo, Turin, Italy) and by
the Italian Ministry of Health and were conducted in compliance with
European laws and policies.
Mice treatment and tissue preparation
HPV16/E2 mice (10 mice/group) were treated daily for 4 weeks
between the 5th and the 6th month of age with the same indinavir,
saquinavir, or lopinavir formulations as used inHIV-infected patients,
in association with ritonavir, commonly used inHIV-infected patients
to increase the absorption and prolong the half-life of HIV-PIs or
coadministered drugs. Indinavir (Merck Sharp & Dohme) or Saquin-
avir (Roche, 1.4 or 1mg/day, respectively) in association with ritonavir
(AbbVie, 0.68 mg/day), or lopinavir in coformulation with ritonavir
(LPV/r, Abbott, 0.46 mg/0.11 mg/day), was administered by intra-
gastric gavage diluted in 0.2 mL of saline solution, as described
previously (11, 14). These doses were selected to compensate the fact
that inmice the 4-week intragastric gavage can only be performed once
per day, and were found to be well-tolerated in preliminary toxicity
experiments in transgenic mice as well in nude mice (11, 14). The
control group received the same volume of saline solution. Carboplatin
(Sigma-Aldrich, 20 mg/kg) and paclitaxel (Sigma-Aldrich, 15 mg/kg,
kindly provided by Dr. Dario Sangiolo, Medical Oncology Unity,
IRCCS, Candiolo, Turin, Italy) were both administered weekly for
4 weeks by two separated intraperitoneal injections (0.1 mL each), in
association with LPV/r given as described above. Mice were regularly
monitored for changes in weight and health status. At the end of
treatment, mice were euthanized by cervical dislocation after anes-
thesia (isoflurane, intraperitoneal injection) followed by CO2 admin-
istration. Cervices were then excised, embedded in optimal cutting
temperature (OCT) compound, and immediately frozen. The whole
sample was serially cryo-sectioned (10 mm sections) and every fifth
slide was subjected to hematoxylin and eosin staining for tumor
grading in a blinded fashion, as described previously (28). The total
tumor volume was determined by using the formulaV¼ 2/3A Z,
where A is the largest cross-sectional area of the tumor as determined
by imaging using a BX-60 Microscope (Olympus) equipped with a
color Qicam Fast 1394-digital CCD Camera 12 bits (QImaging Corp.)
and Z is the depth of the tumor, as determined through serial
sections (25).
Human cervix specimens
Human cervical specimens [normal cervix, n ¼ 4; low-grade
dysplasia (CIN1), n ¼ 4; high-grade dysplasia (CIN2/3), n ¼ 4; and
cervical squamous carcinoma (cervical carcinoma, n ¼ 4)] were
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obtained from women who underwent surgery without preoperative
therapy at the Candiolo Cancer Institute, IRCCs-FPO (Candiolo,
Turin, Italy) in 2019. The tissue specimens, derived from leftover of
surgical samples to be discarded after the histologic diagnosis, were
completely anonymized and recorded by disease stage. The study was
conducted in accordance with the Code of Ethics of theWorldMedical
Association (Declaration of Helsinki) and within the guidelines and
regulations defined by the Research Ethics Committee for Human
Biospecimen Utilization (Department ofMedical Sciences—ChBU) of
the University of Turin (Candiolo, Turin, Italy). Considering that no
patients’ data were used and that specimens were completely anon-
ymized with no impact on patient care, no specific written informed
consent was required by the competent ethics committee.
IHC analysis
IHC for collagen IV and TIMP-3 was performed on frozen sections
from mice or formalin-fixed, paraffin-embedded human sections
(10-mm thick), respectively. Paraffin sections were deparaffinized with
xylene and rehydrated with decreasing concentrations of ethanol in
water and antigen retrieval was achieved by heating sections in sodium
citrate buffer (pH 6.0) for 7 minutes in a 750-W microwave oven,
followed by 20 minutes of cooling at room temperature. Sections
were then pretreated with 3% H2O2 for 20 minutes and blocked with
serum-free Protein Block (Dako) for 1 hour at room temperature.
Tissues were incubated with rabbit anti-collagen IV polyclonal anti-
body (ab6586, Abcam) or rabbit anti-TIMP-3 polyclonal antibody
(PA5-70423, Invitrogen) overnight at 4C. Samples were then washed
and incubated for 1 hourwith an anti-rabbitHRP-conjugated antibody
(Dako) and antigenswere revealedwith 3,3-diaminobenzidine (Sigma-
Aldrich) according to the manufacturer’s instructions. Sections were
counterstained with hematoxylin and visualized with a BX-60 Micro-
scope (Olympus) equipped with a color Qicam Fast 1394-digital CCD
Camera 12 bits (QImaging Corp.). The expression levels of collagen IV
or TIMP-3 were quantified by ImageJ software by analyzing three
fields/mouse (for collagen IV) or three fields/section (for TIMP-3).
Immunofluorescence analysis
Immunofluorescence analysis was performed on frozen sections
(10 mm) that were air-dried, fixed in zinc-fixative [6.05 g Tris, 0.35 g
Ca(C2H3O2)2, 2.5 g Zn(C2H3O2)2, 2.5 g ZnCl, and 3.8 mL HCl 37%]
for 10minutes, blocked in 3%BSA and 5%donkey serum in 1PBS as
detailed previously (29, 30) and incubated for 1 hour at room
temperature with the following primary antibodies: rabbit anti-Ki67
mAb (1:100 dilutions, RM-9106, Thermo Fisher Scientific), rat
anti-Panendothelial Cell antigen mAb (Meca32) (1:100, 550563, BD
Pharmingen), rabbit anti-NG2 Chondroitin Sulfate Proteoglycan
polyclonal antibody (1:100, AB5320, EMD Chemicon), rat anti-plate-
let–derived growth factor receptor (PDGFR)-a (1:100, 14-140182,
e-Biosciences), goat anti-PDGFR-b (1:100, AF 1042, R&D Systems),
rat anti-mouse F4/80 (1:100, MCA497GA, Bio-Rad), rabbit anti-
cleaved caspase 3 mAb (1:100, 9664S, Cell Signaling Technology),
rabbit anti-MMP-9 (N-terminal) polyclonal antibody (1:100, 10375-2-
AP, Proteintech Group Inc), rabbit anti-TIMP-3 polyclonal antibody
(1:100, PA5-70423, Invitrogen), and mouse GVM39 mAb specifically
recognizing the VEGF:VEGFR2 complex (1:50, CD300, EastCoast
Bio).The secondary antibodies used were conjugated to Alexa Fluor
555 or Alexa Fluor 488 Fluorochromes (1:200, Invitrogen). Cell nuclei
were counterstained with DAPI (1:5,000, Invitrogen). All immune-
localization experiments were performed on multiple tissue sections
(5 mice/treatment group) and included negative controls for deter-
mination of background staining.
Confocal microscopy and immunofluorescence
quantifications
All immunofluorescence imageswere captured by using a Leica TCS
SPE Confocal Laser-scanning Microscope (three fields/mouse, Leica
Microsystems) and by maintaining the same laser power, gain, and
offset settings. To quantify pericyte coverage (a-NG2, red channel or
PDGFR-b, green channel) in each image, a region of interest (ROI)
close to each blood vessel (Meca32, green channel or red channel for
PDGFR-b) was selected and the fluorescence of the red and green
channels was quantified using the Leica Confocal Software Histogram
Quantification Tool (Leica Microsystems; ref. 30). The ratio of red to
green channel mean fluorescence intensity was then calculated and
values were expressed as the percentage of red to green costaining. A
similar procedure, by using ImageJ software, was followed to quantify
the apoptotic rate in endothelial cells by evaluating the colocalization
ratio between caspase 3 (green channel) and Meca32 (red channel), to
quantify the colocalization of the VEGF/VEGFR complex (red chan-
nel) and Meca32 (green channel), and to measure the colocalization
ratio between TIMP3 (red channel) and Meca32 (green channel). The
colocalization between TIMP-3 (red channel) and PDGFR-a or F4/80
(green channel) was quantified, as described above, by calculating the
ratio between the two channels and values were expressed as percent-
age of red/green costaining. To determine the expression levels of Ki67
(red channel), caspase 3 (green channel), MMP-9 (green channel), and
TIMP-3 (green channel), the fluorescence of three randomROIs of the
same size was measured and values were normalized by comparing
stained areas with the total cells present in that specific tissue area
visualized by DAPI.
Tumor vasculature analysis
The surface area occupied by vessels was quantified through the
Image-ProPlus 6.2 Software (Media Cybernetics; three fields/mouse),
as described previously (30). Briefly, the area occupied by Meca32-
positive structures was compared with the total tissue area visualized
by DAPI. To analyze vessel branching and diameter, confocal images
were analyzed with the imaging software winRHIZO Pro (Regent
Instruments Inc.). This software reproduces vessel pattern, identifies
vessel branching, and gives back forks (blood vessel branch points) per
area. Branching was calculated as number of forks relative to total
vessel area (three fields/mouse).
Tumor hypoxia analysis
The levels of tumor hypoxia were evaluated in cervical lesions of
HIV-PI–treated and control mice 2 hours after intraperitoneal injec-
tion of 60mg/kg pimonidazole hydrochloride (HP2-100Hypoxyprobe
Kit-Plus, Natural Pharmacia International Inc., 5 mice/group), as
described previously (25, 29–31). Hypoxyprobe-1-Mab 1 FITC anti-
body (Chemicon/Millipore) was used on cervical frozen sections to
detect the formation of pimonidazole adducts, according to the
manufacturer’s instructions. Confocal images were captured and
analyzed by using confocal laser-scanning as described above, and
pimonidazole quantification was performed by using the Leica Con-
focal Software Histogram Quantification Tool (three fields/mouse,
Leica Microsystems).
In situ zymography
To evaluate the gelatinolytic activity within cervical lesions, an
in situ zymography was performed on frozen sections from all
treatment groups (25). Substrate was prepared by dissolving 1 mg
DQ Gelatin (Thermo Fisher Scientific) in 1.0 mL Milli-Q water, and
this was further diluted 1:50 in a reaction buffer containing 50mmol/L
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Tris-HCl, 150 mmol/L NaCl, 5 mmol/L CaCl2, and 0.2 mmol/L
sodium azide (pH 7.6). Tissue sections were coated with 250 mL of
substrate, covered with parafilm, and incubated in a dark humidity
chamber at 37C for 2 hours. Sections were then rinsed with Milli-Q
water and fixed in 4% neutral-buffered formalin for 10 minutes in the
dark. Sections were then rinsed in PBS two times, for 5 minutes each,
and mounted with glycerol containing DAPI to counterstain the
nuclei. To verify the contribution of MMPs, control slides were
preincubated with 20 mmol/L EDTA for 1 hour. Confocal images
were captured, analyzed, and quantified by confocal laser-scanning as
described above.
Real-time RT-PCR analysis
Total RNA was purified from pools of snap-frozen tissues (3 mice/
treatment group) using TriReagent (Sigma-Aldrich) according to the
manufacturer’s instructions and quantified by the RNA 6000 Nano
Assay kit in anAgilent 2100 Bioanalyzer (Agilent Technologies). Equal
amounts (100 ng) of total RNA were reverse transcribed by High
Capacity cDNA Archive Kit (Thermo Fisher Scientific). The samples
were analyzed by using the following TaqManGene ExpressionAssays
(Thermo Fisher Scientific) to detect the corresponding mouse tran-
scripts: Mm00600163_m1 (for MMP-9), Mm01341361_m1 (for
TIMP-1), Mm00441825_m1 (for TIMP-2), Mm00441826_m1 (for
TIMP-3), and Mm01184417_m1 (for TIMP-4). Gene expression
was quantitatively analyzed by using the ABI PRISM 7900HT Fast
Real-Time PCR System (Thermo Fisher Scientific). Mouse TATA box
protein probe (Mm01277042_m1) was employed as endogenous
control detector for normalization. Similar results were obtained with
GAPDH (Mm99999915_g1) as housekeeping gene. All measurements
were performed in duplicates. Raw data were analyzed using the
SDS2.2 Software (Applied Biosystems) to define relative quantity.
Statistical analyses
Student t test for independent samples or Wilcoxon–Mann–
Whitney test was performed to evaluate differences between controls
and each treatment group. Statistical analyses were carried out at two-
sided with a 0.05 significance level, using SAS (version 9.4, SAS
Institute Inc.).
Results
HIV-PIs block the progression of cervical cancer in HPV16/E2
mice
HPV16/E2 female mice were treated daily with HIV-PIs starting
at the 5th month of age, when all animals show high-grade (CIN
III) lesions or advanced tumors with a measurable mass (25, 28). In
two independent sets of experiments, 10 mice per group received
indinavir or saquinavir boosted with ritonavir (IDV/r or SQV/r),
or LPV/r, respectively. A group of 10 animals receiving the buffer
were the controls in both experiments. Animals were treated with
HIV-PI doses comparable with those as employed in HIV-infected
patients or patients with classical Kaposi sarcoma (11, 14, 23).
After 1 month of treatment, mice were sacrificed and the tumor
volume was measured. In the groups receiving IDV/r, SQV/r, or
LPV/r, the tumor mass volume was reduced by 84%, 91%, and 91%,
respectively, as compared with control mice (P ¼ 0.0002; P <
0.0001; Fig. 1A and B). Strikingly, the mean tumor mass at the end
of IDV/r, SQV/r, or LPV/r treatment was also significantly smaller
than the tumor volume that was measured in HPV16/E2 mice at
5 months of age (representing the HIV-PI treatment starting point,
P ¼ 0.0004, P ¼ 0.0002, and P ¼ 0.0003, respectively), suggesting
that these drugs efficiently promote tumor regression. Neither
systemic nor organ toxicity was observed in treated animals.
To assess themechanisms underlying the observed antitumor effect
of HIV-PIs, sections of cervical lesions of HIV-PI–treated or control
mice were assessed for the expression of the Ki67 cell proliferation
marker, which has a prognostic value for survival in women with
cervical carcinoma (32). Results indicated that Ki67 expression was
significantly decreased within the tumor mass of mice treated with
IDV/r, SQV/r, or LPV/r as compared with controls, in which Ki67 was
highly expressed in both the epithelial basal layer andwithin the tumor
mass (P < 0.0001; Fig. 1C and D).
Together, these findings indicate that treatment with HIV-PI at
doses comparable with those safely used in HIV-infected patients or
patients with classical Kaposi sarcoma (11, 14, 23) efficiently blocks
tumor progression and promotes tumor regression inHPV16/E2mice
without displaying any significant side effect.
HIV-PIs impair tumor angiogenesis in HPV16/E2 tumors in
association with enhanced apoptosis
To evaluate whether the antitumor property of HIV-PIs was
associated with an effect on the tumor microenvironment (TME), as
observed in other tumor models (11, 12, 14, 18), we assessed the effect
of treatment on the tumor vasculature. To this aim, sections of cervical
lesions of treated or control mice were assessed by immunofluores-
cence for the pan-endothelial cell marker, MECA32. Treatment with
IDV/r, SQV/r, or LPV/r reduced the vessel area by 44%, 41%, and 56%,
respectively, as compared with controls (P < 0.0001 for all treatment
groups; Fig. 2A and B). Interestingly, while the vasculature of control
mice showed an altered morphology with irregular, dilated, and
tortuous vessel, in HIV-PI–treated animals the vessel branching was
markedly reduced and the lumen diameters appeared to be more
regular (Fig. 2A and B).
Tumor treatment with angiogenesis inhibitors can result in apo-
ptosis of both tumor cells and vessel endothelial cells (33). In-line with
the observed antiangiogenic property of HIV-PIs, caspase-3 immu-
nostaining indicated that IDV/r, SQV/r, or LPV/r treatment of
HPV16/E2 mice significantly increased the apoptosis of cervical
lesions in HPV16/E2 mice (P < 0.0001, for all treatment
groups; Fig. 2C). Moreover, confocal analysis demonstrated a statis-
tically significant increase of apoptosis in tumor-associated vascula-
ture of treated mice as compared with controls (P < 0.0001; Fig. 2D).
These results indicate that HIV-PI treatment hampers the survival of
both tumor cells and tumor-associated endothelial cells.
HIV-PIs promote vessel normalization in HPV16/E2 cervical
tumors and improve the antitumor effects of conventional
chemotherapy
The inhibition of tumor angiogenesis and the reduction of vessel
abnormality byHIV-PIs suggested that these drugs could induce vessel
normalization, a process occurring in response to distinctive anti-
angiogenic therapies that renders the tumor vasculature more efficient
in delivering oxygen and drugs. Because the increase in pericyte
coverage of blood vessels is a key marker of tumor vessel
normalization (34–37), a double staining of tumor tissues for pericyte
(NG-2) and endothelial (MECA32) cell markers was performed.
Noteworthy, a 57%, 66%, and 82% increase in pericyte vessel coverage
was observed in HPV16/E2 mice treated with IDV/r, SQV/r, and
LPV/r, respectively, as compared with controls (P < 0.0001, for all
treatment groups; Fig. 3A and B). A significant increase of pericyte
coverage was also demonstrated by double staining of LPV/r-treated
lesions withMeca32 and PDGFR-bþ, another pericyte marker, further
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indicating that indeed HIV-PI treatment increased the fraction of
vessels associated with pericytes (P < 0.0001; Supplementary Fig. S1).
Notably, a quantitative analysis of vessels stained with anti-Meca32
antibody by confocal microscopy, further demonstrated that HIV-PIs,
by reducing the tumor vessel branching and diameters (P <
0.0001; Fig. 3C and D), indeed promote tumor vessel normalization.
To assess whether the changes of tumor vessel phenotype were
associated with an improvement of vessel functionality, hypoxia levels
were evaluated in LPV/r-treated or control tumors by means of
pimonidazole adduct immunostaining, a candidate biomarker of
cancer aggressiveness (31). Remarkably, LPV/r treatment significantly
decreased tumor hypoxia by 57% as compared with control mice (P <
0.0001; Fig. 3E).
Finally, to evaluate whether tumor vessel normalization promoted
byHIV-PIs may enhance the delivery and the antitumor activity of the
standard-of-care chemotherapeutic regimen in women with cervical
carcinoma, tumor-bearing HPV16/E2 mice were treated weekly with
carboplatin/paclitaxel in association with daily LPV/r, or with LPV/r
or carboplatin/paclitaxel alone, for 4 weeks. Remarkably, when LPV/r
was administered in association with carboplatin/paclitaxel, residual
tumors were significantly smaller as compared with carboplatin/
paclitaxel alone (P ¼ 0.0081), LPV/r alone (P ¼ 0.0349), or controls
(P ¼ 0.0080; Fig. 3F), without displaying additional toxicity. Of note,
the tumor volume of LPV/r-treated mice was significantly smaller as
compared with carboplatin/paclitaxel-treated animals (P ¼ 0.0082),
indicating that HIV-PIs have a more potent antitumor activity in
HPV16/E2 mice than conventional chemotherapy (Fig. 3F). Alto-
gether, these data indicate that HIV-PIs promote the normalization of
tumor vasculature morphology and functionality.
HIV-PIs inhibit MMPs activity and reduce MMP-9 expression
We have previously demonstrated that the antiangiogenic and
antitumor effects of HIV-PIs are due to blocking of MMPs expression
and activation (11, 14, 15, 19). To investigate themolecularmechanism
by which HIV-PIs exert their antiangiogenic and pronormalizing
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Figure 1.
HIV-PI treatment inhibits progression of cervical cancer and impairs tumor cell proliferation in HPV16/E2 mice. A and B, Box plots of cervical tumor mass evaluated
using serial cervical sections (see Materials andMethods) frommice treatedwith IDV/r or SQV/r (A), or LPV/r (B), as comparedwith controls, sacrificed at the end of
treatment (6 months of age) or at 5 months of age (treatment starting point) (n ¼ 10 mice/group). A significant reduction of the tumor mass was evidenced in all
treatment groups as compared with controls and with 5-month-old mice, by the unpaired Mann–Whitney U test (#, IDV/r, SQV/r, or LPV/r vs. control and x, IDV/r,
SQV/r, or LPV/r vs. start point). C and D, Immunofluorescence staining of Ki67 (red channel) in representative cervical cross-sections from HPV16/E2 mice treated
with IDV/r or SQV/r (C), or LPV/r (D), and controls mice (scale bars, 50 mm). The relative box plots show that the percentage of proliferating Ki67þcells over the total
tissue areawas significantly decreased inmice treatedwith IDV/r, SQV/r (by 59%), or LPV/r (by 72%) comparedwith their respective controls. Resultswere analyzed
by nonparametric two-tailed, unpaired Mann–Whitney U test (n ¼ 5 mice/group).
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HIV-PI treatment restrains tumor-associated angiogenesis in associationwith increased apoptosis in HPV16/E2 tumors.A and B, Confocal analysis of Meca32 (green
channel) staining in representative HPV16/E2 tumors treated with IDV/r or SQV/r (A), or LPV/r (B), and control mice (scale bars, 50 mm). Box plots represent the
percentage of Meca32-positive cells over the total tissue area for mice treated with IDV/r, SQV/r, or LPV/r, and respective controls. Results were analyzed by
nonparametric two-tailed, unpaired Mann–Whitney U test (n ¼ 5 mice/group). C, Immunofluorescence of caspase 3 (green channel) and Meca32 (red channel) in
representative cervical cross-sections from mice treated with IDV/r, SQV/r, or LPV/r, and control mice (scale bars, 50 mm). Box plots show the rate of apoptotic
(caspase 3þ) cells over the total tissue area formice treatedwith IDV/r, SQV/r, or LPV/r, as comparedwith controls. A statistically significant increase of apoptosis of
2.6-, 2.4-, and 2.2-fold was detected in mice treated with IDV/r, SQV/r, or LPV/r versus controls, respectively. Results were analyzed by nonparametric two-tailed,
unpaired Mann–Whitney U test, (n ¼ 5 mice/group). D, Apoptotic endothelial cells’ rate was quantified as the percentages of caspase 3 and Meca32 costaining
(arrows). An increase of vessel apoptosis of 36.5%, 39.5%, and 40.5%was detected in mice treated with IDV/r, SQV/r, or LPV/r versus controls, respectively. Results
were analyzed by nonparametric two-tailed, unpaired Mann–Whitney U test (n ¼ 5 mice/group); scale bars, 50 mm.
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lesions by an in situ gelatin zymography analysis (14). Treatment with
IDV/r, SQV/r, or LPV/r significantly reduced MMP activity by 69%,
64%, and 72%, respectively, as compared with control buffer (P <
0.0001; Fig. 4A and B).
Among the various MMPs, MMP-9 plays a prominent role in
regulating cervical carcinoma progression and invasion in
HPV16/E2mice, as well as in human cervical carcinoma (15, 17, 25).
Therefore, MMP-9 expression was evaluated in mice cervical
lesions by real-time RT-PCR analysis. MMP-9 gene expression
was significantly reduced in cervical carcinoma of mice treated
with IDV/r, SQV/r, or LPV/r as compared with controls (P ¼
0.0003, P ¼ 0.002, and P ¼ 0.0017, respectively; Fig. 4C and D).
Results from immunofluorescence analysis performed in LPV/r-
treated animals and their controls, indicate that this was associated
with a 43% reduction of MMP-9 protein expression (P < 0.0001;
Supplementary Fig. S2). Thus, treatment with HIV-PIs blocks both
MMP-9 expression and activity in HPV16/E2 mice cervical car-
cinoma lesions.
HIV-PIs restore collagen IV levels in the basementmembrane of
cervical lesions and of tumor vessels
Because collagen IV is a substrate for MMP-9, cervical lesion
sections of mice treated with HIV-PIs or control mice were assessed
for collagen IV expression by immunostaining. Cervical carcinoma
lesions of control mice were characterized by invading nests of cancer
cells without evidence of encirclement by the basement mem-
brane (25, 28) or collagen IV expression (Supplementary Fig. S3). On
the contrary, tumors of mice treated with LPV/r (Fig. 4E) appeared to
be well-encapsulated and expressed significantly higher levels of
collagen IV than controls (by 4.9-fold, P ¼ 0.0051), without evidence
of micro-invasion (28). The same was observed in IDV/r- and SQV/r-
treated mice (P < 0.0001; Supplementary Fig. S3). In addition, treat-
ment with LPV/r significantly increased the amount of collagen IV by
2.7-fold in the basementmembrane of tumor vasculature, as compared
with control mice (P < 0.0001), therefore, indicating a restoration
of the integrity of vascular basement membrane (Fig. 4F), one of the
































































































































































HIV-PI treatment promotes tumor vasculature normalization and enhances antitumor effects of conventional chemotherapy in HPV16/E2 mice. A and B, Vascular
pericyte coverage evaluated by immunostaining with Meca32 (green channel) and the pericyte marker, NG2 (red channel), in representative cervical cross-sections
from HPV16/E2 mice treated with IDV/r or SQV/r (A), LPV/r (B), or controls (scale bars, 50 mm). The amount of pericyte coverage is presented as box plots of the
percentages of NG2 and Meca32 costaining over the total Meca32-positive area. In mice treated with IDV/r, SQV/r, or LPV/r, pericyte coverage was significantly
increased, as compared with controls. Results were analyzed by nonparametric two-tailed, unpaired Mann–Whitney U test (n¼ 5 mice/group). Confocal images of
vessels stainedwith anti-Meca-32 antibodywere used to quantify vessel branching (C) and diameters (D). Box plots show the reduction of vessel branching (by 67%)
and vessel diameter (by 52%) in tumors treated with LPV/r compared with controls. Results were analyzed by nonparametric two-tailed, unpaired Mann–Whitney U
test (n¼ 5 mice/group). E, Tumor hypoxia was assessed by means of pimonidazole adducts (green) immunofluorescence in serial sections of cervical tumors from
mice treatedwith LPV/r or controls (scale bars, 50 mm). A significant decrease of hypoxia (by 57%) in lesions from LPV/r-treatedmice as comparedwith controlswas
evidenced. Results were analyzed by nonparametric two-tailed, unpaired Mann–Whitney U test (n¼ 5 mice/group). F, Box plots of cervical tumor mass from mice
treated with carboplatin (CP)/paclitaxel (PTX), LPV/r, or LPV/r þ carboplatin/paclitaxel, as compared with controls. A significant reduction of tumor mass was
evidenced in all treatment groups as compared with controls, as well as in LPV/r versus carboplatin–paclitaxel, and in LPV/rþ carboplatin/paclitaxel versus LPV/r or
versus carboplatin/paclitaxel-treated mice. Results were analyzed by nonparametric two-tailed, unpaired Mann–Whitney U test (n ¼ 6 mice, control; n ¼ 6 mice,
carboplatin/paclitaxel; n ¼ 6 mice, LPV/r; and n ¼ 5 mice, LPV/r þ carboplatin/paclitaxel).
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HIV-PIs inhibit MMPgelatinolytic activity, reduceMMP-9 expression, and restore the basementmembrane integrity in HPV16/E2 tumors.A andB,Confocal images of
the in situ gelatin zymography (green) of representative cervical sections frommice treated with IDV/r or SQV/r (A), LPV/r (B), or controls (scale bars, 50 mm). Box
plots show the percentage of gelatinolytic area over the total tissue area for IDV/r-, SQV/r-, or LPV/r-treated animals as compared with control mice. Gelatinolytic
activity was greatly reduced in all treatment groups as compared with controls, as assessed by the nonparametric two-tailed, unpaired Mann–Whitney U test (n¼ 5
mice/group).C andD,Real-timeRT-PCRquantification ofMMP-9RNAexpression in cervical tissues fromHPV16/E2mice. The copy number ofMMP-9RNAmolecules
fromsnap-frozen tissue samples ofmice treatedwith IDV/r or SQV/r (C), or LPV/r (D)was normalized on control. A reduction ofMMP-9gene expression by57%, 38%,
and 58% was detected in mice treated with IDV/r, SQV/r, or LPV/r, respectively, as compared with control. Results were analyzed by Student t test (n ¼ 3 mice/
group). E and F, Confocal images of collagen IV expression at the basement membrane of cervical lesions and vessels in representative cervical cross-sections from
mice treatedwith LPV/r or controls. Basementmembrane integrity expressionwas quantified as the percentage of collagen IV–stained area over the total tissue area
in the tumor lesions (E) or as percentage of colocalization of collagen IV with Meca32 in vessels (F). Results were analyzed by nonparametric two-tailed, unpaired
Mann–Whitney U test (n ¼ 3 mice per group); scale bars, 50 mm.
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findings indicate that HIV-PI treatment promotes a reversion of the
invasive behavior of cervical carcinoma toward a more benign
phenotype.
TIMP-3 expression in HIV-PI–treated HVP16/E2 cervical tumors
and in human CIN/cervical carcinoma specimens
The function ofMMPs is regulated by theTIMP-1/4 present inmost
human tissues (38, 39). To further unveil the mechanism for HIV-PI
inhibitory effect on MMP activity, TIMP-1/4 gene expression was
evaluated in tumors of treated and control mice by RT-PCR. Treat-
ment with IDV/r, SQV/r, or LPV/r increased TIMP-3 expression by
2.5-, 2.1-, or 2.7-folds, respectively, as compared with control mice
(P ¼ 0.0058, P ¼ 0.0036, P ¼ 0.0006, respectively; Fig. 5A). Interest-
ingly, this effect occurred in the absence of a significant modulation of
the expression of the other TIMPs (Supplementary Fig. S4A–S4C). The
effect ofHIV-PI treatment onTIMP-3 expressionwas confirmed at the
protein level by immunofluorescence analysis, showing extremely low
levels of TIMP-3 protein expression within untreated tumors and a
significant increase after IDV/r, SQV/r, and LPV/r treatment (P <
0.0001, for all treatment groups; Supplementary Fig. S5A and S5B).We
then investigated which components of TME were responsible for the
HIV-PI–promoted TIMP-3 expression. By double immunostaining
and confocal analysis of LPV/r-treated tumors, we observed a signif-
icant increase of TIMP-3 expression in PDGFR-aþ fibroblasts
(Fig. 5B), the most abundant cancer-associated fibroblast (CAF)
subpopulation present in HPV16/E2 cervical carcinoma (40), and in
tumor-associated F4/80þ macrophages (Fig. 5C), a tumor-infiltrating
immune cell that, by expressing MMP-9, plays a crucial role in
HPV16/E2 CIN/cervical carcinoma progression (25), as compared
with controls (P < 0.0001). Moreover, TIMP-3 expression byMeca32þ
vascular cells was significantly higher in LPV/r-treated tumors than in
controls (Fig. 5D; P < 0.0001), suggesting that tumor vessel normal-
ization promoted byHIV-PI treatment was the result of the restoration
of the balance between pro- and antiangiogenic molecules.
Because, to be best of our knowledge, there are no reports in the
literature about TIMP-3 expression in humanCIN/cervical carcinoma
lesions, we performed a pilot IHC study to assess TIMP-3 protein levels
in human cervical carcinoma specimens as compared with normal
cervix and low/high-grade dysplasia, to evaluate the relevance of our
experimental findings in human tumors. Remarkably, we observed
high levels of TIMP-3 protein expression in normal cervix and a
gradual decrease of staining in low- and high-grade dysplastic lesions.
Moreover, TIMP-3 was not detectable in cervical carcinoma (Fig. 5E).
These data are in agreement with our preclinical data showing down
modulation of TIMP-3 in mice cervical carcinoma and its overexpres-
sion upon LPV/r treatment, and with previous observations indicating
increasing MMPs expression/activity both in human lesions and mice
during CIN/cervical carcinoma progression (17, 25), further confirm-
ing that this model well recapitulates the human disease.
HIV-PI–treated tumors present reduced VEGF/VEGFR complex
levels
It has been shown that MMP-9 regulates the angiogenic switch
during cancer progression (20) and is able to mobilize VEGF and to
increase its association with VEGFR2 in HPV16/E2 mice (25). More-
over, other studies have demonstrated that, independently of its MMP
inhibitory activity, TIMP-3 interferes with angiogenesis by directly
blocking the binding of VEGF to the VEGFR2 (38). To further
investigate the significance of MMP-9 inhibition and TIMP-3 induc-
tion by HIV-PIs, HPV16/E2 tumors from treated and control mice
were stained with an mAb that specifically recognizes VEGF in
complex with VEGFR2 (GVM39) on tumor vasculature (25). Treat-
ment with IDV/r, SQV/r, or LPV/r significantly reduced the levels of
the VEGF/VEGFR complex by 82%, 79%, and 85%, respectively, as
compared with controls (P < 0.0001; Fig. 6A and B). Taken together,
these findings suggest that vessel normalization by HIV-PIs could be
due, at least in part, to a blockade of VEGF downstream signaling
owing to the inhibition of MMP-9 and upregulation of TIMP-3.
Discussion
Antiretroviral treatment of HIVþ women has reduced the onset
and progression of HPV-related uterine cervical lesions, and ulti-
mately the incidence of invasive cervical carcinoma (10, 17).
Although part of this effect is conceivably due to the amelioration
of the immune response, previous work from us and other groups
indicates that HIV-PIs exert direct antitumor and antiangiogenic
effects, which are independent of their antiviral activity and
may significantly contribute to tumor inhibition and regres-
sion (11, 14, 17, 18, 41, 42). This study has examined the effective-
ness and the mechanism(s) of action of both first- and second-
generation HIV-PIs, including indinavir, saquinavir, and lopinavir,
boosted by ritonavir, in a well-established HPV16 E6/E7 transgenic
mouse model of spontaneous cervical carcinogenesis (25, 28–30, 43).
Herein, we show that therapeutic doses of HIV-PIs are effective at
inhibiting cervical carcinoma progression and tumor-associated
angiogenesis, as well as at promoting lesion regression in transgenic
mice through several mechanisms that may operate concurrently.
First, HIV-PI treatment was associated with a reduced MMP-9
expression and activity within murine cervical carcinoma. Of note, we
have previously demonstrated by genetic knockout or pharmacologic
inhibition that MMPs, and in particular MMP-9, play a key role in the
development or progression of cervical carcinoma and in the angio-
genic switch at the CIN/cervical carcinoma transition (25). In this
context, we also showed that HIV-PI concentrations corresponding to
the drug peak levels detectable in plasma of treated individuals can
efficiently block the growth and invasion of CIN cells through a
concomitant reduction of MMP-9 expression and activity by targeting
the AKT/Fra-1 signaling pathway (15, 16, 19). This suggests that the
inhibition ofMMP-9 expression/activity observed uponHIV-PI treat-
ment ofHPV16/E2mice is part of themechanismbywhich these drugs
impair angiogenesis and tumor progression.
In agreement with the reduced MMP-9 activity promoted by
HIV-PIs, we also observed, in treated mice, an increased expression
of collagen IV, one of the main ECM substrate of MMP-9, associated
with the restoration of ECM at both the epithelial basal layer and
endothelial basement membrane. Because loss of collagen IV and
membrane integrity are events associated with tumor invasion and
metastases (38, 42), these data indicate that HIV-PIs can revert the
invasive behavior of cervical lesions of HPV16/E2 mice toward a more
benign phenotype.
Noteworthy, a previously unknown effect observed in HIV-PI–
treated HPV16/E2 mice was the enhanced expression of the MMP-9
endogenous inhibitor, TIMP-3, concomitantly to the reduction of
MMP levels and activity in mice lesion. TIMP-3 behaves as a tumor
suppressor and inhibitor of angiogenesis and is downregulated in
several tumor types. Interestingly, we also showed here, for the first
time, that TIMP-3 is highly expressed in human normal cervix speci-
mens and that its expression is gradually downregulated during CIN/
cervical carcinoma progression, indicating that the data obtained in
HPV16/E2 mice are relevant for human tumors. It is, therefore,
conceivable that the reduced gelatinolytic activity observed in
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HIV-PI–treated mice may be due, at least in part, to the inhibition of
MMP activity by TIMP-3. Of note, a marked reduction of the
expression or activity of MMP-inhibiting molecules, including
TIMP-1, TIMP-2, and reversion-inducing cysteine-rich protein with
Kazal motifs (RECK), was also observed in human invasive/advanced
cervical carcinoma, as compared with normal cervical tissue or CIN
lesions, in association with increase in MMP-2 and -9 (44).
Consistent withMMP-9downregulation andTIMP-3 upregulation,
HIV-PI–treated mice showed a reduced vessel density associated to a
strong decrease of VEGF/VEGFR2 complex in tumors. One explana-
tion of these effects is provided by HIV-PIs’ capability of down-
regulating MMP-9, which may lead to a decreased mobilization of
sequestered, ECM-bound VEGF (20, 25), and, at the same time, of












































































































































































































TIMP-3 expression is increased in tumor
cells and TME of HIV-PI–treated tumors and
is lost during humanCIN/cervical carcinoma
(CC) progression. A, Real-time RT-PCR
quantification of TIMP-3 RNA expression
highlights a significant reduction of TIMP-3
gene expression in cervical tissues from
HIV-PI–treated tumors as compared with
controls. The copy number of TIMP-3 RNA
from snap-frozen tissue samples from mice
treated with IDV/r, SQV/r, or LPV/r was
normalized on control tumors. Results were
analyzed by Student t test (n ¼ 3 mice/
group). Confocalmicroscopy of TIMP-3 (red
channel) and CAFs (PDGFR-a; B), macro-
phages (F4/80; C), or vessels (Meca32;
green channels; D) in representative cervi-
cal sections from mice treated LPV/r and
control animals (scale bars, 50 mm). Box
plots show the percentage of colocalization
between TIMP-3 and PDGFR-a or F4/80 or
Meca32. TIMP-3 protein expression in fibro-
blasts, macrophages, and vessels of LPV/r-
treaded mice was increased by 10.8-, 7.4-,
and 5.7-folds, respectively, as compared
with control. Results were analyzed by non-
parametric two-tailed, unpaired Mann–
Whitney U test (n ¼ 5 mice/group). E,
Immunostaining of TIMP3 protein expres-
sion in human cervix specimens. In normal
cervix, TIMP-3 presents a diffuse cyto-
plasmic and nuclear localization within cer-
vical epithelium and cervical stromal cells
(fibroblasts and endothelium), which
becomes less intense and scattered in
CIN-1 lesions. In CIN-2/3 lesions, TIMP-3
only displays a cytoplasmic immunoreac-
tivity in scattered fibroblasts, whereas it is
absent in invasive cervical carcinoma. TIMP-
3 expression levels are presented as box
plots of the percentages of TIMP-3–positive
area/field. Results were analyzed by non-
parametric two-tailed, unpaired Mann–
Whitney U test (n ¼ 4 patients/group).
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catalytic site, but also the VEGF binding to VEGFR2 (38), as observed
here.
Although further studies are required to ascertain a causal rela-
tionship between HIV-PI antitumor effects and TIMP-3 upregulation
in transgenic mice, evidence from the literature indicates that addi-
tional mechanisms may also be involved. For instance, the HIV-PIs,
nelfinavir and amprenavir, downregulate VEGF expression in tumor
cells in vitro and in vivo by inhibiting the PI3K/Akt pathway (41, 42),
which alsomodulatesMMP-9 expression (15, 19). Moreover, HIV-PIs
may conceivably interrupt the positive transcriptional feedback loop
betweenVEGF andMMPs (45), which aremolecules playing a key role
in HPV-promoted cervical tumorigenesis. Indeed, both MMP-9 and
VEGF have been shown to be upregulated already in early cervical
carcinoma stages of transgenic mice or patients with cervical carci-
noma (17, 25) due to the activity of HPV E6 and E7 oncoproteins (46).
Remarkably, our study showed for the first time that HIV-PI
antitumor and antiangiogenic effects are associated with the normal-
ization of vessels structure and functionality, as indicated by the
increased vessel pericyte coverage and relieve of local tumor hypoxia.
In this regard, it is well known that tumor vessels are tortuous, leaky,
and poorly covered by pericytes, factors leading not only to tumor
hypoxia, which is known to activate several pathways contributing to
tumor invasion and metastasis (34, 47–49), but also to low drug
penetration into the tumor mass. The factors inducing and sustaining
these vessels abnormalities are several, including induction of angio-
genic factors (i.e., VEGF) and downregulation of angiogenesis inhi-
bitors, such as TIMPs (35, 37, 43, 44, 50).The impairment of MMP-9
and VEGF availability along with the upregulation of TIMP-3 could
represent a mechanism by which HIV-PIs are capable of restoring the
balance between pro- and antiangiogenic factors and, consequently, of
normalizing the vasculature. However, in addition to this, the endo-
thelial cell–pericyte interaction is known to induce TIMP-3 expres-
sion (51), suggesting that the upregulation of TIMP-3 may also be
consequent to vessel normalization promoted by HIV-PI treatment.
Notably, we observed that in HIV-PI–treated tumors, TIMP-3 expres-
sion was increased within different TME cell types playing a key role in
CIN/cervical carcinoma progression of HPV16/E2 mice (25, 40).
Altogether, these data indicate that the antitumor and antiinvasive
effects ofHIV-PIs inHPV16/E2micemay be attributed, at least in part,
to their capability of reverting protumoral CAFs, macrophages, and
vasculature to a “normalized” phenotype.
These results are of great interest, because it is known that anti-
angiogenic therapies can result in a worsening of tumor hypoxia,
which, in turn, fuels a vicious circle further promoting tumor pro-
gression and treatment resistance (34). On the contrary, therapeutic
strategies aimed at vessel normalization and at decreasing or prevent-
ing tumor hypoxia may overcome the problem of escape resistance to
treatment (29, 34, 35, 52). Indeed, the identification of novel targets
for tumor vessel normalization is at the forefront of cancer
research (30, 34–36, 53). In this context, the anti-VEGF mAb, bev-
acizumab, has demonstrated clinical efficacy in recurrent and meta-
static cervical carcinoma when combined with conventional chemo-
therapy, and is now thefirst biologic drug approved for use in late-stage
cervical carcinoma (54), indicating that treatments aimed at targeting
tumor vasculature could represent a novel and alternative therapeutic
strategy in cervical carcinoma. Remarkably, in our study, HIV-PIs
used as single agent not only impaired invasive cervical carcinoma, but
normalized tumor vasculature and significantly reduced tumor hyp-
oxia, suggesting that these drugs, by acting on TME, could prevent or
overcome tumor cell resistance to treatments. In agreement with this
hypothesis, we showed here that HIV-PIs not only have more potent
































































Tumor vessels of HIV-PI–treated mice present reduced levels of VEGF/VEGFR2 complex. Confocal microscopy of VEGF/VEGFR2 complex assessed by GV39M
antibody (red channel) and endothelial cells (EC) visualized with the anti-Meca-32 antibody (green) in representative cervical cross-sections frommice treated with
IDV/r or SQV/r (A), LPV/r (B), or controls (arrows); scale bars, 50mm. The extent of VEGFR2 occupancy byVEGF in ECs in cervical tissue frommice treatedwith IDV/r
or SQV/r (A), or LPV/r (B), and controlmice are represented as box plots of the percentages ofGVM39/Meca32 costaining area over the total tissue area. A significant
reduction of the VEGF/VEGFR2 complex was evidenced by nonparametric two-tailed, unpaired Mann–Whitney U test (n ¼ 5 mice/group).
Qiu et al.
Mol Cancer Ther; 19(12) December 2020 MOLECULAR CANCER THERAPEUTICS2486
on April 13, 2021. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Published OnlineFirst October 20, 2020; DOI: 10.1158/1535-7163.MCT-20-0055 
of-care regimen for cervical carcinoma, but also enhanced chemo-
therapy antitumor activity, without additional toxicity.
Finally, in this study, we also observed a reduction of Ki67 expres-
sion in HIV-PI–treated mice, which is a marker of poor prognosis for
women with cervical carcinoma (32), and they increased apoptosis
within the tumor mass and tumor vessels. Previous studies indicated
that the induction of apoptosis in endothelial or cancer cells, including
cervical carcinoma cells and HPV16-immortalized and -transformed
cells, occurred only at molar concentrations of HIV-PIs, which are
much higher than those used here and measured in plasma of HIVþ-
treated patients, likely through a proteasome-mediated mechanism(s)
involving p53 stabilization and upregulation of the antiviral protein
ribonuclease L, and with different potency by the different HIV-
PIs (11, 13–15, 17, 21). This suggests that the enhanced apoptosis
observed in HIV-PI–treated transgenic mice may be due to other
mechanisms, such as TIMP-3 induction (55, 56) and/or inhibition of
VEGF signaling (33).
Despite worldwide campaigns for screening programs for the
detection and surveillance of CIN lesions and for a global coverage
against HPV by preventative vaccination, the burden ofHPVþwomen
at risk of CIN/cervical carcinoma development currently remains very
high, particularly in low-resource settings. Furthermore, no therapies
are available to eradicate or block persistent HR-HPV infection, the
cause of nearly 100% of all cervical carcinomas. There is, therefore, a
strong need for new approaches against HR-HPV and cervical carci-
noma capable of preventing CIN progression, and to develop effective
and tolerable second-line therapies in advanced cervical carcinoma. In
this context, HIV-PIs may represent a new alternative intervention to
current invasive treatments for CIN, including surgical interventions,
which are often accompanied by short-term (local hemorrhage, infec-
tions, and lesion of proximal organs) or long-term (cervical stenosis,
infertility, and preterm births) side effects or lesion persistence/
recurrence (57, 58).
Several trials conducted with HIV-PIs in patients with cancer,
including HIV-negative Kaposi sarcoma or CIN (23, 24), indicated
that HIV-PIs have good tolerability and promising antitumor
activity. Our results may also open perspectives for new dosing
and delivery systems, including drug formulations for topical
therapy to locally achieve persistently high drug concentrations
promoting proteasome-mediated HIV-PI effects (13, 17), leading to
simplified treatments that may benefit HIVþ or seronegative men
and women at risk of HPV-associated cancers. In addition, based on
their capability of normalizing tumor vessel, these drugs could be
combined with conventional cytotoxic antitumor drugs or other
targeted immunotherapy thus, addressing the unmet clinical need
for effective and tolerable second-line therapies in advanced cervical
carcinoma (54). Most HIV-PIs are already available as generic drugs
thus, HIV-PI drug repositioning for cervical carcinoma therapy
may strongly impact the costs for national health systems, partic-
ularly in developing countries. Because HIV-PIs are already in
clinical use, and have a well-known toxicological and pharmaco-
logic profile, these results may rapidly provide strong indications for
their use in women with CIN/cervical carcinoma infected or
noninfected by HIV.
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